Substantial Holder's Percentage Ownership Drops, Signaling Significant Dilution
ATHE sits 69% above its 52-week low of $2.66.
Summary
Alterity Therapeutics' ADR depositary reported a drop in its percentage ownership, implying significant dilution from new share issuance by the company.
Key Events · Financing and Capital Events · ATHE
-
Substantial Holder's Percentage Ownership Decreased
The Bank of New York Mellon Corporation's voting power in Alterity Therapeutics Limited decreased from 28.16% to 26.22%.
-
Absolute Share Count Increased for Depositary
The depositary's absolute shareholding increased from 2,735,828,317 to 2,851,674,748 ordinary shares.
-
Implied Significant Share Dilution
The increase in absolute shares held by the depositary, coupled with a decrease in its percentage ownership, indicates a substantial increase in Alterity Therapeutics' total outstanding shares, leading to significant dilution for existing shareholders.
Analysis · ATHE · Life Sciences
The Bank of New York Mellon Corporation, acting as the depositary for Alterity Therapeutics' ADR program, reported a decrease in its percentage voting power from 28.16% to 26.22%. This occurred despite an increase in the absolute number of shares held by the depositary, indicating a substantial increase in the company's total outstanding shares. This implied dilution can significantly impact per-share metrics and investor sentiment, suggesting the company has raised capital through new share issuance.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 36.1% of the 1753 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.04%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ATHE was trading at $4.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $77.7M. The 52-week trading range was $2.66 to $7.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.